{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T04:08:19Z","timestamp":1788926899524,"version":"build-2803163510"},"reference-count":179,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Hematology"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/16078454.2026.2720973","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T03:55:10Z","timestamp":1788926110000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Frontline therapies for adult patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia: a systematic literature review"],"prefix":"10.1080","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1591-8999","authenticated-orcid":false,"given":"Maria Virginia","family":"Meza","sequence":"first","affiliation":[{"name":"Global Health Economics, Amgen Inc.","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4065-6728","authenticated-orcid":false,"given":"Sarah","family":"Hodgkinson","sequence":"additional","affiliation":[{"name":"Scientific Affairs, Oxford PharmaGenesis","place":["Oxford, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9753-4823","authenticated-orcid":false,"given":"Christian Stefan","family":"Eichinger","sequence":"additional","affiliation":[{"name":"Scientific Affairs, Oxford PharmaGenesis","place":["Oxford, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0758-4630","authenticated-orcid":false,"given":"Faraz","family":"Zaman","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Amgen Inc.","place":["Thousand Oaks, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Boyko","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Amgen Inc.","place":["Thousand Oaks, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"e_1_3_5_2_1","volume-title":"Acute Lymphoblastic Leukemia Treatment (PDQ\u00ae)\u2013Health Professional Version","author":"National Cancer Institute","year":"2025","unstructured":"National Cancer Institute. Acute Lymphoblastic Leukemia Treatment (PDQ\u00ae)\u2013Health Professional Version. Bethesda, MD, US: National Cancer Institute; 2025. [updated 2025 Mar 17; cited 2026 Jan 29]. Available from: https:\/\/www.cancer.gov\/types\/leukemia\/hp\/adult-all-treatment-pdq"},{"key":"e_1_3_5_3_1","volume-title":"Cancer Stat Facts: Leukemia \u2014 Acute Lymphocytic Leukemia (ALL)","author":"National Cancer Institute","year":"2025","unstructured":"National Cancer Institute. Cancer Stat Facts: Leukemia \u2014 Acute Lymphocytic Leukemia (ALL). Bethesda, MD, US: National Cancer Institute Surveillance, Epidemiology, and End Results Program (SEER); 2025. [cited 2026 Jan 29]. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/alyl.html"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-018192"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-232124"},{"key":"e_1_3_5_6_1","volume-title":"National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Acute Lymphoblastic Leukemia, Version 1.2026","author":"National Comprehensive Cancer Network","year":"2026","unstructured":"National Comprehensive Cancer Network. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Acute Lymphoblastic Leukemia, Version 1.2026. Plymouth Meeting, PA: National Comprehensive Cancer Network; 2026. [updated April 8, 2026]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/all.pdf"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2003.11.003"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.201053"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70546-1"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0085554"},{"key":"e_1_3_5_11_1","volume-title":"Cancer Facts & Figures 2019","author":"American Cancer Society","year":"2019","unstructured":"American Cancer Society. Cancer Facts & Figures 2019. Atlanta, GA: American Cancer Society; 2019 [cited Jan 29, 2026]. Available from: https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/cancer-facts-figures-2019.html"},{"key":"e_1_3_5_12_1","volume-title":"Survival for Acute Lymphoblastic Leukaemia (ALL)","author":"Cancer Research UK.","year":"2024","unstructured":"Cancer Research UK. Survival for Acute Lymphoblastic Leukaemia (ALL). London, UK: Cancer Research UK; 2024. [updated 2024 Sep 06; cited 2026 Jan 28]. Available from: https:\/\/www.cancerresearchuk.org\/about-cancer\/acute-lymphoblastic-leukaemia-all\/survival"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020794"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017009845"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10880-012-9304-5"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1188\/15.ONF.E91-E101"},{"key":"e_1_3_5_17_1","volume-title":"Single Technology Appraisal: Blinatumomab for Treating Minimal Residual B-Precursor Acute Lymphoblastic Leukaemia in Remission [ID1036]","author":"National Institute for Health and Care Excellence.\u200b","year":"2019","unstructured":"National Institute for Health and Care Excellence.\u200b Single Technology Appraisal: Blinatumomab for Treating Minimal Residual B-Precursor Acute Lymphoblastic Leukaemia in Remission [ID1036]. London, UK: National Institute for Health and Care Excellence; 2019. [updated 2019 Jul 24; cited 2026 Jan 29]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta589\/documents\/committee-papers-2"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-020-00591-4"},{"key":"e_1_3_5_19_1","volume-title":"Chemotherapy (DA-EPOCH+\/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia","author":"National Cancer Institute","year":"2026","unstructured":"National Cancer Institute. Chemotherapy (DA-EPOCH+\/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia. Bethesda, MD, US: National Library of Medicine; 2026. [updated May 11, 2026; cited 2026 Jul 4]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05453500"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2309701"},{"key":"e_1_3_5_21_1","volume-title":"BLINCYTO\u00ae (blinatumomab) for injection, for intravenous use","author":"Amgen","year":"2026","unstructured":"Amgen. BLINCYTO\u00ae (blinatumomab) for injection, for intravenous use. Thousand Oaks, CA: Amgen, Inc.; 2026. [updated April 2026; cited 2026 Jan 28]. Available from: www.pi.amgen.com\/-\/media\/Project\/Amgen\/Repository\/pi-amgen-com\/blincyto\/blincyto_pi_hcp_english.pdf"},{"key":"e_1_3_5_22_1","volume-title":"RITUXAN\u00ae (rituximab) injection, for intravenous use","author":"Genentech","year":"2021","unstructured":"Genentech. RITUXAN\u00ae (rituximab) injection, for intravenous use. South San Francisco, CA: Genentech, Inc.; 2021. [updated 2021 Dec; cited 2026 Jan 28]. Available from: https:\/\/www.gene.com\/download\/pdf\/rituxan_prescribing.pdf"},{"key":"e_1_3_5_23_1","volume-title":"BESPONSA (inotuzumab ozogamicin) for injection, for intravenous use","author":"Wyeth Pharmaceuticals LLC","year":"2024","unstructured":"Wyeth Pharmaceuticals LLC. BESPONSA (inotuzumab ozogamicin) for injection, for intravenous use. Philadelphia, PA: Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.; 2024. [updated 2024 Mar; cited 2026 Jan 29]. Available from: https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=9503"},{"key":"e_1_3_5_24_1","volume-title":"MONJUVI\u00ae (tafasitamab-cxix) for injection, for intravenous use","author":"Incyte Corporation","year":"2025","unstructured":"Incyte Corporation. MONJUVI\u00ae (tafasitamab-cxix) for injection, for intravenous use. Wilmington, DE: Incyte; 2025. [updated June 2025; cited 2026 July 4]. Available from: https:\/\/www.incytepicentral.com\/sites\/g\/files\/hssmmz4016\/files\/2025-06\/monjuvi-prescribing-information-1906.pdf#page=1"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-019-1172-8"},{"key":"e_1_3_5_26_1","first-page":"280.","volume-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"Wells G","year":"2021","unstructured":"Wells G , Shea B , O'Connell D , et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa, ONT, Canada: The Ottawa Hospital Research Institute; 2021. p. 280. [updated 2021 May 3; cited 2025 Aug 19]. Available from: https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"key":"e_1_3_5_27_1","volume-title":"Risk of bias tools","author":"Bristol Evidence synthesis Appraisal and Modelling (BEAM) Centre","year":"2023","unstructured":"Bristol Evidence synthesis Appraisal and Modelling (BEAM) Centre. Risk of bias tools. Bristol, UK: University of Bristol; 2023. [cited Jan 28, 2026]. Available from: https:\/\/www.riskofbias.info\/"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-01968-8"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146306"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-199060"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.283"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00383-2"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1605085"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00038-2"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000967372.19440.62"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-171751"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-209438"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-189648"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312948"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-207143"},{"issue":"1","key":"e_1_3_5_41_1","first-page":"26","article-title":"Addition of blinatumomab to consolidation therapy for younger adults BCR:ABL1-negative B-acute lymphoblastic leukemia (ALL) on the ECOG-ACRIN E1910 phase III trial","volume":"9","author":"Dinner SSZ","year":"2025","unstructured":"Dinner SSZ , Paietta E , Mattison R , et al. Addition of blinatumomab to consolidation therapy for younger adults BCR:ABL1-negative B-acute lymphoblastic leukemia (ALL) on the ECOG-ACRIN E1910 phase III trial. HemaSphere. 2025;9(Supplement 1):26\u201328.","journal-title":"HemaSphere"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-156080"},{"issue":"1","key":"e_1_3_5_43_1","first-page":"650","article-title":"Blinatumomab alternating with low-intensity chemotherapy (LIC) in older adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL): safety run-in follow-up for the phase 3 Golden Gate study","volume":"8","author":"Jabbour EAI","year":"2024","unstructured":"Jabbour EAI , Aldoss I , Fleming S , et al. Blinatumomab alternating with low-intensity chemotherapy (LIC) in older adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL): safety run-in follow-up for the phase 3 Golden Gate study. HemaSphere. 2024;8(Supplement 1):650\u2013651.","journal-title":"HemaSphere"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.conctc.2016.06.004"},{"issue":"16","key":"e_1_3_5_45_1","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1182\/bloodadvances.2022009596","article-title":"Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial","volume":"5","author":"Bassan R","year":"2023","unstructured":"Bassan R , Chiaretti S , Della Starza I , et al. Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial. Blood Adv. 2023;5(16):4448\u20134461.","journal-title":"Blood Adv"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25784"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1397661"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007311"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.229"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-014-0938-z"},{"issue":"1","key":"e_1_3_5_51_1","first-page":"S56","article-title":"Non-intensive but non-interruptive treatment without high-dose blocks is an effective strategy for adult Ph-negative acute lymphoblastic leukemia: the first interim results of the Russian prospective multicenter RALL-2016 study","volume":"98","author":"Gavrilina O","year":"2019","unstructured":"Gavrilina O , Parovichnikova E , Troitskaya V , et al. Non-intensive but non-interruptive treatment without high-dose blocks is an effective strategy for adult Ph-negative acute lymphoblastic leukemia: the first interim results of the Russian prospective multicenter RALL-2016 study. Ann Hematol. 2019;98(Suppl 1):S56.","journal-title":"Ann Hematol"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124701"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(25)01510-1"},{"issue":"1","key":"e_1_3_5_54_1","first-page":"3221","article-title":"The first results of the RALL-2016m protocol: \u201cMRD-status\u201d based target therapy for Ph-negative acute lymphoblastic leukemia in adult patients","volume":"8","author":"Aleshina O","year":"2024","unstructured":"Aleshina O , Kotova E , Isinova G , et al. The first results of the RALL-2016m protocol: \u201cMRD-status\u201d based target therapy for Ph-negative acute lymphoblastic leukemia in adult patients. HemaSphere. 2024;8(S1):3221\u20133222.","journal-title":"HemaSphere"},{"issue":"1","key":"e_1_3_5_55_1","first-page":"2230","article-title":"MRD-based target therapy for Ph-negative acute lymphoblastic leukemia in adult patients by the RALL-2016m protocol: effective for BCP-all, shows no efficacy in T-ALL","volume":"9","author":"Aleshina OKE","year":"2025","unstructured":"Aleshina OKE , Vasilieva A , Kotova E , et al. MRD-based target therapy for Ph-negative acute lymphoblastic leukemia in adult patients by the RALL-2016m protocol: effective for BCP-all, shows no efficacy in T-ALL. HemaSphere. 2025;9(Supplement 1):2230\u20132231.","journal-title":"HemaSphere"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-10-881961"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159397"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.70168"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-199435"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025029611"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1780583"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-798322"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-190902"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-181379"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000968344.67564.ca"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.7034"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157358"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27576"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-208854"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-1567"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000968372.81147.9d"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-151826"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01766"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-174973"},{"issue":"2","key":"e_1_3_5_75_1","first-page":"8","article-title":"Preliminary results of the GIMEMA LAL2317 sequential chemotherapy-blinatumomab frontline trial for newly diagnosed adult Ph-negative B-lineage ALL patients","volume":"5","author":"Bassan R","year":"2021","unstructured":"Bassan R , Chiaretti S , Della Starza I , et al. Preliminary results of the GIMEMA LAL2317 sequential chemotherapy-blinatumomab frontline trial for newly diagnosed adult Ph-negative B-lineage ALL patients. HemaSphere. 2021;5(S2):8.","journal-title":"HemaSphere"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027500"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-180472"},{"key":"e_1_3_5_78_1","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1182\/blood-2021-146214","article-title":"Dose reduced chemotherapy in sequence with blinatumomab for newly diagnosed older patients with B-precursor adult lymphoblastic leukemia (ALL): results of the ongoing GMALL bold trial","volume":"138","author":"Goekbuget N","year":"2021","unstructured":"Goekbuget N , Stoltefuss A , Topp M , et al. Dose reduced chemotherapy in sequence with blinatumomab for newly diagnosed older patients with B-precursor adult lymphoblastic leukemia (ALL): results of the ongoing GMALL bold trial. Blood. 2021;138:3399.","journal-title":"Blood"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000844352.62588.a4"},{"issue":"1","key":"e_1_3_5_80_1","first-page":"30","article-title":"Blinatumomab added to prephase and consolidation therapy in adult B-ALL: a comparison of the consecutive HOVON-100 AND H-146 studies","volume":"8","author":"Baalen Eske van PG","year":"2024","unstructured":"Baalen Eske van PG , Bellido M , et al. Blinatumomab added to prephase and consolidation therapy in adult B-ALL: a comparison of the consecutive HOVON-100 AND H-146 studies. HemaSphere. 2024;8(Supplement 1):30\u201331.","journal-title":"HemaSphere"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146163"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-177847"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-643"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157361"},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-174831"},{"issue":"1","key":"e_1_3_5_86_1","first-page":"3214","article-title":"Blinatumomab induction therapy following reduced-dose chemotherapy in newly diagnosed adult Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia: multicentre, single-arm, phase 2 study","volume":"8","author":"Lu JQH","year":"2024","unstructured":"Lu JQH , Qiu H , Wang Y , et al. Blinatumomab induction therapy following reduced-dose chemotherapy in newly diagnosed adult Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia: multicentre, single-arm, phase 2 study. HemaSphere. 2024;8(Supplement 1):3214\u20133216.","journal-title":"HemaSphere"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00073-X"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000968404.35630.66"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000844308.97537.9c"},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-182982"},{"key":"e_1_3_5_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30011-1"},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.7011"},{"key":"e_1_3_5_93_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e19025"},{"key":"e_1_3_5_94_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-154074"},{"key":"e_1_3_5_95_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-208824"},{"key":"e_1_3_5_96_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-148625"},{"key":"e_1_3_5_97_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-166035"},{"key":"e_1_3_5_98_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00490"},{"key":"e_1_3_5_99_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.7006"},{"key":"e_1_3_5_100_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00307"},{"key":"e_1_3_5_101_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-444"},{"key":"e_1_3_5_102_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-145553"},{"key":"e_1_3_5_103_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162235"},{"key":"e_1_3_5_104_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00546"},{"key":"e_1_3_5_105_1","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2022.401"},{"issue":"1","key":"e_1_3_5_106_1","first-page":"144","article-title":"Blinatumomab in CD19 positive precursor B-cell ALL Philadelphia negative disease used to purge bone marrow after the end of induction in patients demonstrating residual bone marrow disease: the impact on progression free survival","volume":"9","author":"Salamoon M","year":"2025","unstructured":"Salamoon M . Blinatumomab in CD19 positive precursor B-cell ALL Philadelphia negative disease used to purge bone marrow after the end of induction in patients demonstrating residual bone marrow disease: the impact on progression free survival. HemaSphere. 2025;9(Supplement 1):144\u2013145.","journal-title":"HemaSphere"},{"key":"e_1_3_5_107_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-208742"},{"key":"e_1_3_5_108_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-5131"},{"issue":"1","key":"e_1_3_5_109_1","first-page":"117","article-title":"Integrated venetoclax with immunochemotherapy in older or unfit patients with newly diagnosed Philadelphia-negative B-cell acute lymphoblastic leukemia (B-ALL): a phase 2 multi-center clinical trial","volume":"9","author":"Gu RZX","year":"2025","unstructured":"Gu RZX , Zhao X, Qiu S , et al. Integrated venetoclax with immunochemotherapy in older or unfit patients with newly diagnosed Philadelphia-negative B-cell acute lymphoblastic leukemia (B-ALL): a phase 2 multi-center clinical trial. HemaSphere. 2025;9(Supplement 1):117\u2013118.","journal-title":"HemaSphere"},{"key":"e_1_3_5_110_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-200713"},{"key":"e_1_3_5_111_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-1554"},{"key":"e_1_3_5_112_1","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70291"},{"issue":"1","key":"e_1_3_5_113_1","first-page":"28","article-title":"Blinatumomab as consolidation in a paediatric protocol leads to high rates of end-consolidation MRD negativity and excellent outcomes in AYA ALL \u2013 final results of the ALLG ALL09 \u201cSUBLIME\u201d study","volume":"8","author":"Greenwood MGS","year":"2024","unstructured":"Greenwood MGS , Gangatharan S, Osborn M , et al. Blinatumomab as consolidation in a paediatric protocol leads to high rates of end-consolidation MRD negativity and excellent outcomes in AYA ALL \u2013 final results of the ALLG ALL09 \u201cSUBLIME\u201d study. HemaSphere. 2024;8(Supplement 1):28\u201329.","journal-title":"HemaSphere"},{"key":"e_1_3_5_114_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-209043"},{"key":"e_1_3_5_115_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.6540"},{"key":"e_1_3_5_116_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.12284"},{"key":"e_1_3_5_117_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2115841"},{"key":"e_1_3_5_118_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01253-6"},{"key":"e_1_3_5_119_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05373-5"},{"issue":"3","key":"e_1_3_5_120_1","first-page":"1","article-title":"Efficacy and tolerability of age-adjusted hyper CVAD in older patients with newly diagnosed acute lymphoblastic leukemia","volume":"25","author":"Covert W","year":"2019","unstructured":"Covert W , Di Pippo A , Mace M , et al. Efficacy and tolerability of age-adjusted hyper CVAD in older patients with newly diagnosed acute lymphoblastic leukemia. J Oncol Pharm Pract. 2019;25(3_suppl):1.","journal-title":"J Oncol Pharm Pract"},{"key":"e_1_3_5_121_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.04.006"},{"key":"e_1_3_5_122_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04738-y"},{"key":"e_1_3_5_123_1","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2019.1567654"},{"key":"e_1_3_5_124_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-013-0519-6"},{"key":"e_1_3_5_125_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-178332"},{"key":"e_1_3_5_126_1","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2021.1900908"},{"key":"e_1_3_5_127_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.12.016"},{"key":"e_1_3_5_128_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.02.009"},{"key":"e_1_3_5_129_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05405-0"},{"key":"e_1_3_5_130_1","doi-asserted-by":"publisher","DOI":"10.4149\/neo_2013_072"},{"key":"e_1_3_5_131_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14125"},{"key":"e_1_3_5_132_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13247"},{"key":"e_1_3_5_133_1","doi-asserted-by":"publisher","DOI":"10.1159\/000489025"},{"key":"e_1_3_5_134_1","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2024.2329027"},{"key":"e_1_3_5_135_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03789-6"},{"key":"e_1_3_5_136_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.632532"},{"key":"e_1_3_5_137_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04277-y"},{"key":"e_1_3_5_138_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26156"},{"key":"e_1_3_5_139_1","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2022.2052602"},{"key":"e_1_3_5_140_1","doi-asserted-by":"publisher","DOI":"10.17305\/bjbms.2022.7851"},{"key":"e_1_3_5_141_1","doi-asserted-by":"publisher","DOI":"10.47102\/annals-acadmedsg.V43N3p152"},{"key":"e_1_3_5_142_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2164193"},{"key":"e_1_3_5_143_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.22207"},{"key":"e_1_3_5_144_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25671"},{"key":"e_1_3_5_145_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-185323"},{"key":"e_1_3_5_146_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0163599"},{"key":"e_1_3_5_147_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14381"},{"key":"e_1_3_5_148_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-203929"},{"key":"e_1_3_5_149_1","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2024.2415589"},{"key":"e_1_3_5_150_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-206854"},{"key":"e_1_3_5_151_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2025.01.003"},{"issue":"1","key":"e_1_3_5_152_1","first-page":"2236","article-title":"Real-world outcomes of Philadelphia chromosome-negative acute lymphoblastic leukemia in adults treated with a pediatric-inspired protocol: a comparison across two time periods","volume":"9","author":"Perusini M","year":"2025","unstructured":"Perusini M , Wei J , Gupta V , et al. Real-world outcomes of Philadelphia chromosome-negative acute lymphoblastic leukemia in adults treated with a pediatric-inspired protocol: a comparison across two time periods. HemaSphere. 2025;9(S1):2236\u20132237.","journal-title":"HemaSphere"},{"issue":"1","key":"e_1_3_5_153_1","first-page":"611","article-title":"CAMPUS ALL multicenter study on outcome of 421 adult ph-negative acute lymphoblastic leukemia patients treated in real-life with an intensive program inspired by the GIMEMA LAL1913 clinical trial","volume":"8","author":"Lazzarotto D","year":"2024","unstructured":"Lazzarotto D , Cerrano M , Papayannidis C , et al. CAMPUS ALL multicenter study on outcome of 421 adult ph-negative acute lymphoblastic leukemia patients treated in real-life with an intensive program inspired by the GIMEMA LAL1913 clinical trial. HemaSphere. 2024;8(S1):611\u2013612.","journal-title":"HemaSphere"},{"issue":"1","key":"e_1_3_5_154_1","first-page":"55","article-title":"Outcome of 421 adult patients with Philadelphia-negative acute lymphoblastic leukemia treated under an intensive program inspired by the GIMEMA LAL1913 clinical trial: a campus ALL study","volume":"110","author":"Lazzarotto D","year":"2025","unstructured":"Lazzarotto D , Cerrano M , Papayannidis C , et al. Outcome of 421 adult patients with Philadelphia-negative acute lymphoblastic leukemia treated under an intensive program inspired by the GIMEMA LAL1913 clinical trial: a campus ALL study. Haematologica. 2025;110(1):55\u201367.","journal-title":"Haematologica"},{"key":"e_1_3_5_155_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.286043"},{"key":"e_1_3_5_156_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-3333"},{"key":"e_1_3_5_157_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e19017"},{"key":"e_1_3_5_158_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146214"},{"key":"e_1_3_5_159_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00766-7"},{"key":"e_1_3_5_160_1","doi-asserted-by":"crossref","DOI":"10.1016\/S2152-2650(25)01556-3","article-title":"ALL-830: prognostic impact of early NGS MRD dynamics and cytomolecular risk in newly diagnosed Philadelphia chromosome-negative B-cell ALL","volume":"25","author":"Nasr L","year":"2025","unstructured":"Nasr L , Macaron W , Kantarjian H , et al. ALL-830: prognostic impact of early NGS MRD dynamics and cytomolecular risk in newly diagnosed Philadelphia chromosome-negative B-cell ALL. Clin Lymphoma Myeloma Leuk. 2025;25:S366","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"e_1_3_5_161_1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41408-025-01373-y","article-title":"Prognostic impact of early NGS MRD dynamics and cytomolecular risk in newly diagnosed B-cell ALL","volume":"15","author":"Short NJ","year":"2025","unstructured":"Short NJ , Jabbour E , Macaron W , et al. Prognostic impact of early NGS MRD dynamics and cytomolecular risk in newly diagnosed B-cell ALL. Blood Cancer J. 2025;15(1):169.","journal-title":"Blood Cancer J"},{"issue":"16","key":"e_1_3_5_162_1","doi-asserted-by":"crossref","first-page":"6535","DOI":"10.1200\/JCO.2025.43.16_suppl.6535","article-title":"Outcomes of ph-like B-lineage acute lymphoblastic leukemia in the era of novel therapies","volume":"43","author":"Youshanlouei HR","year":"2025","unstructured":"Youshanlouei HR , Shah SAM , Anazco F , et al. Outcomes of ph-like B-lineage acute lymphoblastic leukemia in the era of novel therapies. J Clin Oncol. 2025;43(16_suppl):6535\u20136535.","journal-title":"J Clin Oncol"},{"key":"e_1_3_5_163_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-208069"},{"key":"e_1_3_5_164_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-204181"},{"key":"e_1_3_5_165_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-024-01435-1"},{"key":"e_1_3_5_166_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-206184"},{"key":"e_1_3_5_167_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.20200"},{"key":"e_1_3_5_168_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-3336"},{"key":"e_1_3_5_169_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-759"},{"key":"e_1_3_5_170_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-5116"},{"key":"e_1_3_5_171_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-6861"},{"key":"e_1_3_5_172_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13375"},{"key":"e_1_3_5_173_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01460-6"},{"key":"e_1_3_5_174_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00285-X"},{"key":"e_1_3_5_175_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.3112"},{"key":"e_1_3_5_176_1","unstructured":"Canadian Agency for Drugs and Technologies in Health . 2023. Search Filters Database 2023. [cited April 26 2023]. Available from: https:\/\/searchfilters.cadth.ca\/list?q=&p=1&ps=20&setName_facet=ovid%20000000%7COvid)"},{"key":"e_1_3_5_177_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_3_5_178_1","volume-title":"Blincyto\u00ae Consumer Medicine Information (CMI) summary v9","author":"MedAdvisor International Pty Ltd.","year":"2025","unstructured":"MedAdvisor International Pty Ltd. Blincyto\u00ae Consumer Medicine Information (CMI) summary v9. Melbourne, VIC, Australia: MedAdvisor International Pty Ltd.; 2025. [cited Jan 29, 2026]. Available from: https:\/\/apps.medicines.org.au\/files\/ancblinp.pdf"},{"key":"e_1_3_5_179_1","volume-title":"Product Monograph Including Patient Medication Information: BLINCYTO\u00ae (blinatumomab for injection)","author":"Amgen Canada Inc.","year":"2025","unstructured":"Amgen Canada Inc. Product Monograph Including Patient Medication Information: BLINCYTO\u00ae (blinatumomab for injection). Mississauga, ONT, Canada: Amgen Canada Inc.; 2025. [updated 2025 Aug 1; cited 2026 Jan 28]. Available from: https:\/\/www.amgen.ca\/en-ca\/about\/-\/media\/themes\/corporateaffairs\/redesign\/amgen-ca\/amgen-ca\/pdf\/products\/en\/blincyto_pm.pdf"},{"key":"e_1_3_5_180_1","volume-title":"European Public Assessment Report: Blincyto Summary of Product Characteristics","author":"European Medicines Agency.","year":"2015","unstructured":"European Medicines Agency. European Public Assessment Report: Blincyto Summary of Product Characteristics. Amsterdam, The Netherlands: European Medicines Agency; 2015 [cited 2026 Jan 28]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/blincyto-epar-product-information_en.pdf"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/16078454.2026.2720973","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/16078454.2026.2720973","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/16078454.2026.2720973","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T03:55:19Z","timestamp":1788926119000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/16078454.2026.2720973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":179,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/16078454.2026.2720973"],"URL":"https:\/\/doi.org\/10.1080\/16078454.2026.2720973","relation":{},"ISSN":["1607-8454"],"issn-type":[{"value":"1607-8454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=yhem20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=yhem20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-10-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2720973"}}